翔宇医疗：前三季度营收同比增长6% 脑机接口布局打开增长新空间

Core Insights - The company reported a total revenue of 537 million yuan for the first three quarters of 2025, representing a year-on-year growth of 6.00% [1] - The net profit attributable to shareholders for the same period was 43.98 million yuan [1] - In Q3 2025, the company achieved a revenue of 178 million yuan, with a year-on-year increase of 5.5%, and a net profit of 8.59 million yuan [1] Financial Performance - Total revenue for the first three quarters: 537 million yuan, up 6.00% year-on-year [1] - Net profit attributable to shareholders: 43.98 million yuan [1] - Q3 2025 revenue: 178 million yuan, up 5.5% year-on-year [1] - Q3 2025 net profit: 8.59 million yuan; net profit after deducting non-recurring items: 6.91 million yuan [1] Research and Development - The company increased its R&D investment, with expenses reaching 125 million yuan in the first three quarters, a year-on-year growth of 8.85% [1] - The company added 87 new patents, including 30 new invention patents, bringing the total to 1,936 patents [1] - The company also achieved 29 new provincial-level scientific and technological achievements, totaling 277 [1] - The company won the third prize in military scientific and technological progress awards [1] Product Development and Market Expansion - The company is focusing on brain-machine interface technology, with multiple products approved for use [1] - Over 80 large hospitals are currently using the company's brain-machine interface rehabilitation devices [1] - New products equipped with brain-machine interface technology are expected to significantly boost the company's performance in 2026 [1]